Skip to main content
Top
Published in: Journal of Neuro-Oncology 3/2008

01-12-2008 | Clinical Study - Patient Studiies

Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption

Authors: Marcus W. C. MacNealy, Herbert B. Newton, John M. McGregor, Susan D. Bell, Abhik Ray Chaudhury, H. Wayne Slone, Eric C. Bourekas

Published in: Journal of Neuro-Oncology | Issue 3/2008

Login to get access

Abstract

Diffuse large B-cell lymphoma of the meninges is a particularly rare form of primary CNS lymphoma. We report a case of a 63-year-old woman found to have primary meningeal lymphoma (PML) with dural and leptomeningeal involvement whom we treated with multiple cycles of intra-arterial (IA) methotrexate, intravenous (IV) etoposide phosphate, and IV cyclophosphamide after reversible osmotic blood-brain barrier disruption (BBBD). Improvement was evident on gadolinium-enhanced brain MRI one month into therapy. At 67 months post-diagnosis there is no evidence of CNS disease. After completing her therapy regimen, she remained disease-free for 34 months, when stage IV diffuse large B-cell lymphoma was discovered in her left adrenal gland and right thigh. Following six cycles of rituximab and CHOP treatment, she is presently in complete remission. IA methotrexate and reversible osmotic BBBD without radiation therapy may be an effective therapy for treating PML.
Literature
1.
go back to reference Slone HW, Blake JJ, Shah R et al (2005) CT and MRI findings of intracranial lymphoma. AJR 184:1679–1685PubMed Slone HW, Blake JJ, Shah R et al (2005) CT and MRI findings of intracranial lymphoma. AJR 184:1679–1685PubMed
6.
go back to reference Lachance DH, O’Neill BP, Macdonald DR et al (1991) Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology 41:95–100PubMed Lachance DH, O’Neill BP, Macdonald DR et al (1991) Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology 41:95–100PubMed
7.
go back to reference Doolittle ND, Miner ME, Hall WA et al (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88(3):637–647. doi :10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-YPubMedCrossRef Doolittle ND, Miner ME, Hall WA et al (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88(3):637–647. doi :10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-YPubMedCrossRef
11.
go back to reference Bourekas EC, Wildenhain P, Lewin JS et al (1995) The dural tail sign revisited. AJNR Am J Neuroradiol 16:1514–1516PubMed Bourekas EC, Wildenhain P, Lewin JS et al (1995) The dural tail sign revisited. AJNR Am J Neuroradiol 16:1514–1516PubMed
12.
go back to reference Aster JC (2005) Diseases of white blood cells, lymph nodes, spleen, and thymus. In: Kumar V, Abbas AK, Fausto N (eds) Robbins and Cotran pathologic basis of disease, 7th edn. Elsevier, Pennsylvania Aster JC (2005) Diseases of white blood cells, lymph nodes, spleen, and thymus. In: Kumar V, Abbas AK, Fausto N (eds) Robbins and Cotran pathologic basis of disease, 7th edn. Elsevier, Pennsylvania
Metadata
Title
Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption
Authors
Marcus W. C. MacNealy
Herbert B. Newton
John M. McGregor
Susan D. Bell
Abhik Ray Chaudhury
H. Wayne Slone
Eric C. Bourekas
Publication date
01-12-2008
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2008
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-008-9667-5

Other articles of this Issue 3/2008

Journal of Neuro-Oncology 3/2008 Go to the issue

Clinical study - patient Study

M1 Medulloblastoma: high risk at any age